

This is a preview of "ISO 5840-1:2021". [Click here to purchase the full version from the ANSI store.](#)

Second edition
2021-01

Cardiovascular implants — Cardiac valve prostheses —

Part 1: General requirements

*Implants cardiovasculaires — Prothèses valvulaires —
Partie 1: Exigences générales*



Reference number
ISO 5840-1:2021(E)

© ISO 2021



COPYRIGHT PROTECTED DOCUMENT

© ISO 2021

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

This is a preview of "ISO 5840-1:2021". Click here to purchase the full version from the ANSI store.

Contents

	Page
Foreword	v
Introduction	vi
1 Scope	1
2 Normative references	1
3 Terms and definitions	2
4 Abbreviations	15
5 Fundamental requirements	15
6 Device description	16
6.1 General	16
6.2 Intended use	16
6.3 Design inputs	16
6.3.1 Operational specifications	16
6.3.2 Performance specifications	17
6.3.3 Implant procedure	17
6.3.4 Packaging, labelling, and sterilization	17
6.4 Design outputs	18
6.5 Design transfer (manufacturing verification/validation)	18
6.6 Risk management	18
7 Design verification and validation	18
7.1 General requirements	18
7.2 <i>In vitro</i> assessment	18
7.2.1 General	18
7.2.2 Test conditions, sample selection and reporting requirements	19
7.2.3 Material property assessment	20
7.2.4 Hydrodynamic performance assessment	21
7.2.5 Structural performance assessment	21
7.2.6 Design- or procedure-specific testing	23
7.2.7 Device MRI compatibility	23
7.2.8 Simulated use	23
7.2.9 Human factors/usability assessment	23
7.2.10 Implant thrombogenic and haemolytic potential assessment	23
7.3 Preclinical <i>in vivo</i> evaluation	24
7.4 Clinical investigations	24
Annex A (informative) Rationale for the provisions of ISO 5840-1	25
Annex B (normative) Packaging	28
Annex C (normative) Product labels, instructions for use, and training	29
Annex D (normative) Sterilization	32
Annex E (normative) <i>In vitro</i> test guidelines for paediatric devices	33
Annex F (informative) Corrosion assessment	37
Annex G (informative) Echocardiographic protocol	40
Annex H (informative) Assessment of implant thrombogenic and haemolytic potential	42
Annex I (informative) Guidelines for hydrodynamic performance characterization by steady flow testing	53
Annex J (normative) Durability testing	60
Annex K (informative) Fatigue assessment	68
Annex L (normative) Clinical investigation endpoints for heart valve replacement devices	73

This is a preview of "ISO 5840-1:2021". [Click here to purchase the full version from the ANSI store.](#)

Bibliography	76
---------------------------	-----------

This is a preview of "ISO 5840-1:2021". [Click here to purchase the full version from the ANSI store.](#)

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 285, *Non-active surgical implants*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This second edition cancels and replaces the first edition (ISO 5840-1:2015), which has been technically revised.

The main changes compared to the previous edition are as follows: the engineering and clinical requirements in the ISO 5840 series have been updated to current specifications and integrated and harmonized across all parts.

A list of all parts in the ISO 5840 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

There is, as yet, no heart valve substitute which can be regarded as ideal.

The ISO 5840 series has been prepared by a group well aware of the issues associated with heart valve substitutes and their development. In several areas, the provisions of the ISO 5840 series deliberately have not been specified to encourage development and innovation. It does specify the types of tests, provides guidance for test methods and test apparatuses and requires documentation of test methods and results. The areas with which the ISO 5840 series are concerned are those which ensure that associated risks to the patient and other users of the device have been adequately mitigated, facilitate quality assurance, aid the clinician in choosing a heart valve substitute, and ensure that the device is presented in a convenient form. Emphasis has been placed on specifying types of *in vitro* testing, preclinical *in vivo* and clinical evaluations, reporting of all *in vitro*, preclinical *in vivo*, and clinical evaluations, and the labelling and packaging of the device. Such a process involving *in vitro*, preclinical *in vivo*, and clinical evaluations is intended to clarify the required procedures prior to market release and to enable prompt identification and management of any subsequent problems.

With regard to *in vitro* testing and reporting, apart from basic material testing for mechanical, physical, chemical, and biocompatibility characteristics, the ISO 5840 series also covers important hydrodynamic and durability characteristics of heart valve substitutes and systems required for their implantation. The ISO 5840 series does not specify exact test methods for hydrodynamic and durability testing, but it offers guidelines for the test apparatus.

The ISO 5840 series is intended to be revised, updated, and/or amended as knowledge and techniques in heart valve substitute technology improve.

This document is used in conjunction with ISO 5840-2 and ISO 5840-3.